| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Coproporphyrin I dihydrochloride does not have a specific biological target; it is a biochemical reagent and porphyrin biomarker. As a porphyrin, it can chelate metals through its porphyrin ring. Its primary use is as an indicator in biochemical and clinical research applications, facilitating the study and monitoring of biological processes and conditions.
|
|---|---|
| ln Vitro |
In vitro, Coproporphyrin I dihydrochloride is used as a biochemical reagent and porphyrin biomarker. It exhibits a characteristic absorption at 395 nm, which can be used for detection and quantification in various assays. The compound's ability to chelate metals makes it useful for studying metal-binding proteins and porphyrin metabolism.
|
| ln Vivo |
No specific in vivo activity data is publicly available for Coproporphyrin I dihydrochloride. As a biochemical reagent and biomarker, it is not typically administered in vivo for therapeutic purposes.
|
| Enzyme Assay |
As a biochemical reagent, Coproporphyrin I dihydrochloride is not evaluated in cell-free receptor binding assays. Its properties are characterized by its absorption spectrum (λmax 395 nm) and its ability to chelate metals. The compound's purity and identity are confirmed by analytical techniques such as HPLC and mass spectrometry.
|
| Cell Assay |
In vitro cell-based experiments with Coproporphyrin I dihydrochloride are limited. It may be used as a standard or reagent in assays for porphyrin metabolism or as a fluorescent probe in certain applications. The compound's characteristic absorption at 395 nm can be used for detection in cell-based assays.
|
| Animal Protocol |
No specific in vivo animal protocols are publicly available for Coproporphyrin I dihydrochloride. As a biochemical reagent, it is not typically used in animal studies for therapeutic purposes.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data is publicly available for Coproporphyrin I dihydrochloride. As a biochemical reagent, its absorption, distribution, metabolism, and excretion (ADME) properties have not been characterized. The compound has a molecular formula of C36H38N4O8·2HCl and a molecular weight of 727.63.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is publicly available for Coproporphyrin I dihydrochloride. As a biochemical reagent, it is considered to have low toxicity at the concentrations used for research applications. The compound is for research use only and is not intended for human consumption.
|
| Additional Infomation |
Coprophyrin I is a coprophyrin. It is a human metabolite. It is the conjugate acid of coprophyrin I(4-). Coprophyrin I has been reported to have been found in Sphingopyxis, and relevant data are available for reference.
Coproporphyrin I dihydrochloride has a molecular formula of C36H38N4O8·2HCl and a molecular weight of 727.63. It is a porphyrin biomarker with an absorption of λmax 395 nm. The compound chelates metals through its porphyrin ring and is used as a biochemical reagent for biomedical research. It is available for research purposes only. |
| Molecular Formula |
C36H40CL2N4O8
|
|---|---|
| Molecular Weight |
727.64
|
| Exact Mass |
726.222
|
| CAS # |
69477-27-6
|
| PubChem CID |
68271
|
| Appearance |
Purple to purplish red solid powder
|
| Boiling Point |
1252.7ºC at 760 mmHg
|
| Flash Point |
711.4ºC
|
| LogP |
4.697
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
48
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C2C=C3C(=C(C)C(=CC4=NC(=CC5=NC(=CC(=C1CCC(=O)O)N2)C(=C5CCC(=O)O)C)C(=C4CCC(=O)O)C)N3)CCC(=O)O.Cl.Cl
|
| InChi Key |
VCCUOZSDXVZCSK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H38N4O8/c1-17-21(5-9-33(41)42)29-14-26-19(3)23(7-11-35(45)46)31(39-26)16-28-20(4)24(8-12-36(47)48)32(40-28)15-27-18(2)22(6-10-34(43)44)30(38-27)13-25(17)37-29/h13-16,37-38H,5-12H2,1-4H3,(H,41,42)(H,43,44)(H,45,46)(H,47,48)
|
| Chemical Name |
3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetramethyl-21,22-dihydroporphyrin-2-yl]propanoic acid
|
| Synonyms |
CP-I; CP I; CPI
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3743 mL | 6.8715 mL | 13.7431 mL | |
| 5 mM | 0.2749 mL | 1.3743 mL | 2.7486 mL | |
| 10 mM | 0.1374 mL | 0.6872 mL | 1.3743 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
